The US Food and Drug Administration (FDA) Safety and Innovation Act of 2012 created the Breakthrough Therapy designation to expedite development and review of drugs and biologics intended to treat serious or life-threatening conditions for which preliminary clinical evidence may demonstrate substantial improvement over existing therapies, allowing the FDA to provide "intensive guidance on efficient drug development" and "rolling review."
The median number of pivotal trials per indication approval was 1 (interquartile range [IQR], 1-2), and the median number of patients enrolled among all pivotal trials supporting an indication approval was 222 (IQR, 124-796). Among these approvals, 27 were made on the basis of pivotal trials using randomization (58.7%), 21 using double-blind allocation (45.7%), 25 using an active or placebo comparator group (54.3%), and 10 using a clinical primary end point (21.7%). Pivotal trials that were used to support breakthrough approvals with Accelerated Approval status were less likely than trials without Accelerated Approval to be randomized ( Table 2) .
The median time from IND activation to FDA approval was 4.9 years (IQR, 2.7-7.6), including 4.1 years (IQR, 2.0-7.0) from IND activation to FDA submission and 6.9 months (IQR, 5.1-8.0) from NDA submission to FDA approval. All 18 approvals (100%) with Accelerated Approval had at least 1 clinical safety or efficacy-focused postmarketing requirement, as did 18 approvals (64.3%) without Accelerated Approval.
Discussion | This study of all FDA approvals granted Breakthrough Therapy designation from 2012 through 2017 suggests that pivotal trials supporting these approvals commonly lacked randomization, double-blinding, and control groups, used surrogate markers as primary end points, and enrolled small numbers of patients. Furthermore, more than half were based on a single pivotal trial. On average, premarket development times were approximately 5 years, consistent with prior investigations, 6 and FDA regulatory review and approval required less than 7 months on average. This study was limited to new drugs granted Breakthrough Therapy designation and receiving FDA approval. Prior research suggests that use of randomization, doubleblinding, control groups, and clinical outcomes is more common among pivotal trials supporting FDA approval of nonBreakthrough Therapy designated drugs, even among those undergoing Accelerated Approval. 4 Patients and physicians may have misconceptions about the strength of evidence supporting breakthrough approvals. 2, 3 FDA-required postmarketing studies will be critical to confirm the clinical benefit and safety of these promising, newly approved therapies.
